Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023)
Johnson & Johnson (JNJ) posted Liabilities from Discontinued Operations of 3590000000.0 for Q1 2023.
Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023) Analysis & Trends
Johnson & Johnson has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at 3590000000.0 in Q1 2023.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 3590000000.0 in Q1 2023, while the trailing twelve-month figure through Jan 2023 was 3590000000.0 (changed N/A YoY) and the FY2023 annual result came in at 3590000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was little changed at 3590000000.0 in Q1 2023 per JNJ's latest filing.
- Over five years, Liabilities from Discontinued Operations peaked at 3590000000.0 in Q1 2023 and troughed at 3590000000.0 in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 1, 2023 | 3.59 Bn |
| Jan 1, 2023 | 3.59 Bn |